Skip to content
Search

Latest Stories

ABPI outlines top priorities for Labour's first 100 days in office

ABPI outlines top priorities for Labour's first 100 days in office

ABPI calls on Labour to urgently appoint a new Chair and Chief Executive to the Medicines and Healthcare products Regulatory Agency (MHRA)

The Association of the British Pharmaceutical Industry (ABPI) has laid out a series of urgent actions it wants the newly elected Labour government to implement within its first 100 days in office.

Among the top priorities, the ABPI has emphasised the urgent need to appoint a new Chair and Chief Executive for the Medicines and Healthcare products Regulatory Agency (MHRA).


Additionally, the ABPI has urged the new government to launch the Life Sciences Manufacturing Capital Grants Facility without delay.

Other measures the ABPI wants Labour to prioritise include:

  • Rapidly passing outstanding UK clinical trials legislation to enhance the UK’s attractiveness for inward investment, including into research within the NHS.
  • Increasing commercial flexibility in the NHS England Commercial Framework for New Medicines to remove barriers for companies to launch new medicines and indications so that NHS patients can access the latest innovative medicines.
  • Supporting the National Institute for Health and Care Excellence (NICE) to rapidly review the ‘severity modifier’ used in medicine appraisals.
  • Re-establishing a cross-government and industry working group to examine progress in implementing vaccination-related policy.
  • Reviewing and responingd to outstanding recommendations for the National Immunisation Programme made by the Joint Committee on Vaccination & Immunisation.

Responding to the new health secretary’s commitment to boosting the economy through the life sciences sector, Richard Torbett, Chief Executive of ABPI, said: “Wes Streeting is right to think about the health system as more than just a public service.

“It is an intrinsic part of our national economy - as an employer, as a driver and adopter of new innovations, and as a place to do cutting-edge research and discovery.”

He emphasised that with the right outlook, the health system could become an “active partner” in life science innovation and discovery.

“It can do more to prevent ill health, through the use of new vaccines and preventative medicines, while also getting people healthy and back to work by removing persistent inequality of access to the most effective treatments,” he added.

Addressing the Tony Blair Institute Future of Britain Conference on Monday, Wes Streeting, Secretary of State for Health and Social Care, said:

“One of the things I've said to my department and to the NHS is we need to rethink our role in government and in our country at large.

“This is no longer simply a public services department. This is an economic growth department, and the health of the nation and the health of the economy are inextricably linked.”

“If we can marry our health and social care system with the incredible life sciences and med tech ecosystem we have in this country, we can be a powerhouse for the life sciences and med tech revolution here in this country and in the world. And that is an economic growth mission.”

During its election campaign, Labour has identified the UK’s life sciences sector as a critical partner for its plans to deliver positive change and economic growth.

Torbett earlier said that a strong industry-government partnership will be vital for continued discovery of breakthrough medical innovation in the UK, ensuring NHS patients are among the earliest beneficiaries of cutting-edge medicines and vaccines worldwide.

He said: “The new government now needs to hit the ground running and rapidly set out a clear, detailed plan for what the government will do in the coming weeks and years to address persistent inequalities in access to medicines and vaccines as well as unlock our sector's true growth potential.”

ABPI’s ‘Manifesto for Investment, Health, and Growth’ outlines a strategy aimed at improving healthcare and equity for NHS patients, enhancing patient access to new medicines through clinical trials, generating additional manufacturing jobs and value within the UK, and creating more highly skilled, well-paid jobs in all parts of the country.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less